Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France, with roots dating back to its founding in 1929. Over the decades, the company has evolved from its origins in fermentation processes to become a fully integrated pharmaceutical organization focused on research, development, manufacturing and commercialization of innovative therapies. With a robust presence in Europe, North America and Asia-Pacific, Ipsen serves patients in more than 100 countries through direct operations and partnerships.
The company’s core business activities span three therapeutic areas: oncology, neurology and rare diseases. In oncology, Ipsen markets products such as Somatuline (lanreotide) for the treatment of neuroendocrine tumors and Decapeptyl (triptorelin) for hormone-sensitive cancers. Within neurology and aesthetics, Dysport (abotulinumtoxinA) is employed in the management of spasticity, cervical dystonia and cosmetic indications. In rare diseases, Ipsen offers therapies including NutropinAq (somatropin), addressing growth hormone deficiencies, and Increlex (mecasermin) for severe primary insulin-like growth factor-I deficiency.
Research and development underpin Ipsen’s commitment to innovation, with a pipeline that features targeted therapies, next-generation formulations and novel mechanisms of action. The company collaborates with academic institutions, biotechnology firms and patient advocacy groups to accelerate discovery and expand its portfolio. Strategic acquisitions, such as those bolstering its rare disease franchise, have reinforced Ipsen’s R&D capabilities and broadened its reach into new modalities, including antibody-drug conjugates and cell therapy approaches.
Governance at Ipsen is led by Chief Executive Officer David Loew, who has steered the company’s transformation since 2019. Supported by an international leadership team, Ipsen emphasizes patient-centric value, operational excellence and sustainable growth. Its manufacturing network spans facilities in France, the United States and Ireland, ensuring global supply continuity. As Ipsen continues to build on its heritage, it remains committed to delivering specialty care solutions that address unmet medical needs and improve patient outcomes worldwide.
AI Generated. May Contain Errors.
Free IPSEY Stock Alerts